RxDoctor Payments Data

Henry Morris, MD

Family Medicine · Athens, GANPI 1629063771

Payments from drug & device makers

$16,448in general payments, 2019–2025

Across 66 payments — averaging $249.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$15K
  • Abbott$182
  • Novo Nordisk$182
  • Xeris Pharmaceuticals, Inc.$129
  • AstraZeneca$120
  • Lilly USA, LLC$108
  • plus $682 from 16 others

What the payments were for

  • Consulting fees$3,24920%
  • Speaking & faculty fees$10,65565%
  • Travel & lodging$6454%
  • Food & beverage$1,82911%
  • Education$120%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,448 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$254,277
Medicare patients
593
Services billed
5,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide267$293,560
JardianceEmpagliflozin173$205,988
OzempicSemaglutide124$163,311
EliquisApixaban144$127,508
FarxigaDapagliflozin Propanediol111$118,721
Soliqua 100-33Insulin Glargine/Lixisenatide98$116,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$47,818
XifaxanRifaximin14$47,215
TrulicityDulaglutide33$45,337
XareltoRivaroxaban38$42,952
Tresiba Flextouch U-200Insulin Degludec31$33,035
JanuviaSitagliptin Phosphate28$29,599
RybelsusSemaglutide13$27,113
Lyumjev Kwikpen U-100Insulin Lispro-Aabc21$26,293
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/720$25,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$108$338,898300 claims
Novo NordiskOzempic, Rybelsus$182$190,424137 claims
PfizerEliquis$86$127,508144 claims
AstraZenecaFarxiga$120$118,721111 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$75$116,93298 claims
AbbVieLinzess$38$11,93211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →